floxuridine has been researched along with Neoplasm Metastasis in 84 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 10.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "We performed a phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer based on UDP-glucuronosyltransferase (UGT) 1A1 polymorphism." | 9.17 | UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer. ( Araki, A; Eto, R; Hazama, S; Hinoda, Y; Kanekiyo, S; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Uchiyama, T; Yamamoto, T; Yoshida, S; Yoshino, S, 2013) |
| "Our objectives were to determine response rate, time to progression, overall survival and tolerability of novel combination chemotherapy, consisting of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin in advanced previously untreated colorectal cancer." | 9.12 | A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. ( Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT, 2007) |
| "This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)." | 9.10 | Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 9.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "This study demonstrates that a home therapy with oral doxifluridine in elderly advanced colorectal cancer patients is feasible, with a relatively low rate of toxicity, and has moderate activity, comparable to that of intravenous 5-fluorouracil." | 9.07 | Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. ( Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994) |
| "This study aimed to compare the efficacy and safety of HAI fluoropyrimidine (FUDR)/capecitabine or single capecitabine as first-line treatment for elderly patients with unresectable colorectal liver metastases (CLMs)." | 7.83 | First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases. ( Ding, W; Ji, M; Jiang, J; Li, X; Lu, Q; Qiang, W; Shi, L; Wu, C; Wu, J; Zhao, J, 2016) |
| "The results support a role for p53 "hot spot" mutations in colorectal liver metastasis resistance to fluorinated pyrimidines, and suggest that the presence of such mutations may be a contra-indication to treatment of colorectal liver metastases with hepatic arterial floxuridine." | 7.71 | P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. ( Allen-Mersh, TG; Feldmann, KA; Ivison, A; Jonas, SK; Khan, ZA; Patel, H; Tarragona, A; Wharton, RQ, 2001) |
| "Twenty-seven patients with advanced colorectal cancer were enrolled in this study, and the UGT1A1*28 polymorphism was genotyped before chemotherapy." | 6.75 | Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. ( Araki, A; Hazama, S; Hinoda, Y; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Yoshida, S; Yoshino, S, 2010) |
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 6.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "The benefits from medical treatment in colorectal cancer are limited." | 5.28 | Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992) |
| "We performed a phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer based on UDP-glucuronosyltransferase (UGT) 1A1 polymorphism." | 5.17 | UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer. ( Araki, A; Eto, R; Hazama, S; Hinoda, Y; Kanekiyo, S; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Uchiyama, T; Yamamoto, T; Yoshida, S; Yoshino, S, 2013) |
| "Our objectives were to determine response rate, time to progression, overall survival and tolerability of novel combination chemotherapy, consisting of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin in advanced previously untreated colorectal cancer." | 5.12 | A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. ( Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT, 2007) |
| "This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)." | 5.10 | Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 5.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "This study demonstrates that a home therapy with oral doxifluridine in elderly advanced colorectal cancer patients is feasible, with a relatively low rate of toxicity, and has moderate activity, comparable to that of intravenous 5-fluorouracil." | 5.07 | Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. ( Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994) |
| "This study aimed to compare the efficacy and safety of HAI fluoropyrimidine (FUDR)/capecitabine or single capecitabine as first-line treatment for elderly patients with unresectable colorectal liver metastases (CLMs)." | 3.83 | First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases. ( Ding, W; Ji, M; Jiang, J; Li, X; Lu, Q; Qiang, W; Shi, L; Wu, C; Wu, J; Zhao, J, 2016) |
| "Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas and hepatic metastases." | 3.73 | Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. ( Amidon, GL; Landowski, CP; Song, X; Vig, BS, 2005) |
| "The results support a role for p53 "hot spot" mutations in colorectal liver metastasis resistance to fluorinated pyrimidines, and suggest that the presence of such mutations may be a contra-indication to treatment of colorectal liver metastases with hepatic arterial floxuridine." | 3.71 | P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. ( Allen-Mersh, TG; Feldmann, KA; Ivison, A; Jonas, SK; Khan, ZA; Patel, H; Tarragona, A; Wharton, RQ, 2001) |
| "The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors." | 3.66 | [Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983) |
| "In developing a chemotherapeutic program for children with disseminated neuroblastoma, we established three human neuroblastoma lines in cell culture to study the effects of dibutyryl cyclic AMP, papaverine, 5-trifluoromethyl-2'-deoxyuridine, and cyclophosphamide on cell growth, biochemical behavior, and morphology." | 3.65 | A rationale for the treatment of metastatic neuroblastoma. ( Das, SK; Helson, C; Helson, L; Peterson, RF, 1976) |
| "Twenty-seven patients with advanced colorectal cancer were enrolled in this study, and the UGT1A1*28 polymorphism was genotyped before chemotherapy." | 2.75 | Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. ( Araki, A; Hazama, S; Hinoda, Y; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Yoshida, S; Yoshino, S, 2010) |
| "In all, 101 patients with metastatic breast cancer were enrolled in the study, and the data for 94 eligible patients of these were evaluated." | 2.71 | The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. ( Goto, T; Kasumi, F; Kutomi, G; Makita, M; Nishimura, S; Tada, K; Tanabe, M; Tokudome, N; Yoshimoto, M, 2003) |
| " Only BILT significantly influenced the pharmacokinetics but this effect was not considered as relevant for dosing adjustment." | 2.71 | Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ( Lokiec, F; Rezaí, K; Urien, S, 2005) |
| "Unresectable colorectal liver metastases are a significant clinical problem." | 2.70 | Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. ( Alexander, HR; Bartlett, DL; Figg, WD; Fraker, DL; Libutti, SK, 2001) |
| "Metastatic renal cell carcinoma patients with measurable disease entered the study." | 2.68 | Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. ( Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Giulianotti, PC; Lencioni, M; Mosca, F; Pfanner, E; Ricci, S; Vannucci, L, 1996) |
| "In 7 patients with recurrence/metastases, FDG-PET and WBS gave corresponding results (10 sites)." | 2.68 | Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. ( Bender, H; Biersack, HJ; Franckson, T; Grünwald, F; Menzel, C; Palmedo, H; Ruhlmann, J; Willkomm, P, 1997) |
| "Metastatic renal cell carcinoma (RCC) is largely chemoresistant." | 2.67 | A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. ( Carroll, PR; Ernest, ML; Frye, JW; Small, EJ; Stagg, RJ; Wilkinson, MJ, 1994) |
| "A PR of hepatic metastases was noted in eight patients (35%) with a median and mean duration of response of 4." | 2.64 | Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. ( Buroker, T; Correa, J; Fraile, R; Samson, M; Vaitkevicius, VK, 1976) |
| "Hepatic metastasis is usually quite resistant to conventional systemic chemotherapy." | 2.36 | Nonsystemic treatment of metastatic tumors of the liver--a review. ( Lee, YT, 1978) |
| "In order to develop a model of liver metastasis of human gastrointestinal cancer cells, we examined the potential of 10 human colon and stomach cancer cell lines (HT-29, WiDr, HCT-116, HCT-15, HCC-2998, MKN7, MKN28, MKN45, MKN74 and St-4) to form liver metastases in nude mice." | 1.34 | Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. ( Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T, 2007) |
| "Capecitabine was also much safer, particularly much less toxic to the intestinal tract, than the other compounds, indicating higher therapeutic indices." | 1.30 | Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine). ( Fukase, Y; Ishikawa, T; Ishitsuka, H; Sekiguchi, F; Yamamoto, T, 1998) |
| "A 58-year-old woman with multiple organ metastases from breast cancer who had undergone radical mastectomy three years ago, was treated with oral 5'-DFUR 600 mg/day." | 1.29 | [A case of breast cancer with multiple organ metastases in which single low dose administration of 5'-DFUR proved effective]. ( Dohi, K; Gotoh, T; Kataoka, T; Nishiki, M; Okamoto, T; Sadamoto, S, 1993) |
| "The benefits from medical treatment in colorectal cancer are limited." | 1.28 | Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992) |
| "Twelve of the patients had primary hepatocellular carcinoma and six had metastatic liver carcinoma originating from an unknown primary site." | 1.27 | Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. ( Benjamin, RS; Chuang, VP; Fuqua, R; Mavligit, GM; Patt, YZ; Wallace, S, 1983) |
| " These dose-response data indicate that locally recurrent tumors are frequently, but not always, different from the original primary tumor in response to chemotherapy agents and ionizing X-irradiation." | 1.27 | Development and characterization of a rat model for locally recurring mammary tumors: sensitivities to 5-fluoro-2'-deoxyuridine, adriamycin, and X-irradiation. ( Aeed, PA; Estrada, J; Welch, DR, 1988) |
| "Of 13 patients with hepatoma, nine had clinically significant regression with a median survival of 11 months." | 1.26 | The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. ( Al-Sarraf, M; Baker, L; Izbicki, R; Reed, ML; Sexon-Porte, M; Singhakowinta, A; Straatsma, GW; Vaitkevicius, VK; Vaughn, CB, 1981) |
| "Forty-eight patients with liver metastases were treated at Rhode ISland Hospital in a nonrandomized sequential manner between January 1972 and June 1977." | 1.26 | A combined treatment approach to management of hepatic metastasis. ( Glicksman, AS; Leone, LA; Rege, VB; Soderberg, CH; Webber, BM, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (55.95) | 18.7374 |
| 1990's | 18 (21.43) | 18.2507 |
| 2000's | 14 (16.67) | 29.6817 |
| 2010's | 5 (5.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Céspedes, MV | 1 |
| Unzueta, U | 1 |
| Aviñó, A | 1 |
| Gallardo, A | 1 |
| Álamo, P | 1 |
| Sala, R | 1 |
| Sánchez-Chardi, A | 1 |
| Casanova, I | 1 |
| Mangues, MA | 1 |
| Lopez-Pousa, A | 1 |
| Eritja, R | 1 |
| Villaverde, A | 1 |
| Vázquez, E | 1 |
| Mangues, R | 1 |
| Kanekiyo, S | 1 |
| Hazama, S | 2 |
| Kondo, H | 2 |
| Nagashima, A | 2 |
| Eto, R | 1 |
| Yoshida, S | 2 |
| Shimizu, R | 2 |
| Araki, A | 2 |
| Yamamoto, T | 2 |
| Uchiyama, T | 1 |
| Yoshino, S | 2 |
| Okayama, N | 2 |
| Hinoda, Y | 2 |
| Oka, M | 2 |
| Li, X | 1 |
| Shi, L | 1 |
| Wu, J | 1 |
| Ji, M | 1 |
| Zhao, J | 1 |
| Qiang, W | 1 |
| Ding, W | 1 |
| Jiang, J | 1 |
| Lu, Q | 1 |
| Wu, C | 1 |
| Lu, X | 1 |
| Ping, Y | 1 |
| Xu, FJ | 1 |
| Li, ZH | 1 |
| Wang, QQ | 1 |
| Chen, JH | 1 |
| Yang, WT | 1 |
| Tang, GP | 1 |
| Saito, Y | 1 |
| Suzuki, Y | 1 |
| Tokuda, Y | 1 |
| Ahn, JH | 1 |
| Kim, TW | 1 |
| Lee, JH | 1 |
| Min, YJ | 1 |
| Kim, JG | 1 |
| Kim, JC | 1 |
| Yu, CS | 1 |
| Kim, WK | 1 |
| Kang, YK | 1 |
| Lee, JS | 1 |
| SULLIVAN, RD | 2 |
| NORCROSS, JW | 1 |
| WATKINS, E | 3 |
| ANSFIELD, FJ | 2 |
| CURRERI, AR | 1 |
| JOHNSON, RO | 1 |
| CASTRO, R | 1 |
| KHAZEI, AM | 2 |
| LAWTON, RL | 1 |
| WILSON, WL | 1 |
| DELAGARZA, JG | 1 |
| Yoshimoto, M | 1 |
| Tada, K | 1 |
| Tokudome, N | 1 |
| Kutomi, G | 1 |
| Tanabe, M | 1 |
| Goto, T | 1 |
| Nishimura, S | 1 |
| Makita, M | 1 |
| Kasumi, F | 1 |
| Wang, HJ | 1 |
| Wang, H | 1 |
| Li, HZ | 1 |
| Shi, BB | 1 |
| Song, ZL | 1 |
| Stadler, WM | 2 |
| Landowski, CP | 1 |
| Vig, BS | 1 |
| Song, X | 1 |
| Amidon, GL | 1 |
| Urien, S | 1 |
| Rezaí, K | 1 |
| Lokiec, F | 1 |
| Schmitz, R | 1 |
| Krakamp, B | 1 |
| Troidl, H | 1 |
| Kato, T | 1 |
| Mishima, H | 1 |
| Ikenaga, M | 1 |
| Murata, K | 1 |
| Ishida, H | 1 |
| Fukunaga, M | 1 |
| Ota, H | 1 |
| Tominaga, S | 1 |
| Ohnishi, T | 1 |
| Amano, M | 1 |
| Ikeda, K | 1 |
| Ikeda, M | 1 |
| Sekimoto, M | 1 |
| Sakamoto, J | 1 |
| Monden, M | 1 |
| Ardalan, B | 1 |
| Kozyreva, O | 1 |
| Tsai, KT | 1 |
| Santos, E | 1 |
| Franceschi, D | 1 |
| Livingstone, A | 1 |
| Lima, M | 1 |
| Ishizu, K | 1 |
| Sunose, N | 1 |
| Yamazaki, K | 1 |
| Tsuruo, T | 1 |
| Sadahiro, S | 1 |
| Makuuchi, H | 1 |
| Yamori, T | 1 |
| Patt, YZ | 2 |
| Chuang, VP | 1 |
| Wallace, S | 2 |
| Benjamin, RS | 2 |
| Fuqua, R | 1 |
| Mavligit, GM | 2 |
| Sommadossi, JP | 1 |
| Aubert, C | 1 |
| Cano, JP | 1 |
| Gouveia, J | 1 |
| Ribaud, P | 1 |
| Mathé, G | 1 |
| Reed, ML | 1 |
| Vaitkevicius, VK | 2 |
| Al-Sarraf, M | 1 |
| Vaughn, CB | 1 |
| Singhakowinta, A | 1 |
| Sexon-Porte, M | 1 |
| Izbicki, R | 1 |
| Baker, L | 1 |
| Straatsma, GW | 1 |
| Balch, CM | 1 |
| Urist, MM | 1 |
| González, ER | 1 |
| Barberi-Heyob, M | 1 |
| Weber, B | 1 |
| Merlin, JL | 1 |
| Dittrich, C | 1 |
| de Bruijn, EA | 1 |
| Luporsi, E | 2 |
| Guillemin, F | 2 |
| Falcone, A | 4 |
| Pfanner, E | 3 |
| Cianci, C | 4 |
| Danesi, R | 1 |
| Brunetti, I | 3 |
| Del Tacca, M | 1 |
| Conte, PF | 3 |
| Ricci, S | 3 |
| Bertuccelli, M | 2 |
| Carrai, M | 1 |
| De Marco, S | 1 |
| Ceribelli, A | 1 |
| Barduagni, M | 1 |
| Calabresi, F | 1 |
| Small, EJ | 1 |
| Frye, JW | 1 |
| Wilkinson, MJ | 1 |
| Carroll, PR | 1 |
| Ernest, ML | 1 |
| Stagg, RJ | 1 |
| Levin, RD | 1 |
| Gordon, JH | 1 |
| Fujimoto-Ouchi, K | 1 |
| Tamura, S | 1 |
| Mori, K | 1 |
| Ishikawa, T | 2 |
| Eda, H | 1 |
| Tanaka, Y | 1 |
| Ninomiya, Y | 1 |
| Ishitsuka, H | 2 |
| Conroy, T | 1 |
| Geoffrois, L | 1 |
| Krakowski, I | 1 |
| Spaëth, D | 1 |
| Frasie, V | 1 |
| Volff, D | 1 |
| Kataoka, T | 1 |
| Okamoto, T | 1 |
| Gotoh, T | 1 |
| Sadamoto, S | 1 |
| Nishiki, M | 1 |
| Dohi, K | 1 |
| Lencioni, M | 1 |
| Giulianotti, PC | 1 |
| Vannucci, L | 1 |
| Mosca, F | 1 |
| Grünwald, F | 1 |
| Menzel, C | 1 |
| Bender, H | 1 |
| Palmedo, H | 1 |
| Willkomm, P | 1 |
| Ruhlmann, J | 1 |
| Franckson, T | 1 |
| Biersack, HJ | 1 |
| Muggia, FM | 1 |
| Jeffers, S | 1 |
| Muderspach, L | 1 |
| Roman, L | 1 |
| Rosales, R | 1 |
| Groshen, S | 1 |
| Safra, T | 1 |
| Morrow, CP | 1 |
| Fukase, Y | 1 |
| Sekiguchi, F | 1 |
| Nakagawa, H | 1 |
| Yamada, M | 1 |
| Maeda, N | 1 |
| Iwatsuki, K | 1 |
| Hirayama, A | 1 |
| Ikenaka, K | 1 |
| Harada, Y | 1 |
| Ohuchi, N | 1 |
| Ohnuki, K | 1 |
| Amano, G | 1 |
| Yoshida, R | 1 |
| Furuta, A | 1 |
| Ikegaki, H | 1 |
| Kijima, G | 1 |
| Satomi, S | 1 |
| Bartlett, DL | 1 |
| Libutti, SK | 1 |
| Figg, WD | 1 |
| Fraker, DL | 1 |
| Alexander, HR | 1 |
| De Larco, JE | 1 |
| Wuertz, BR | 1 |
| Manivel, JC | 1 |
| Furcht, LT | 1 |
| Khan, ZA | 1 |
| Jonas, SK | 1 |
| Feldmann, KA | 1 |
| Patel, H | 1 |
| Wharton, RQ | 1 |
| Tarragona, A | 1 |
| Ivison, A | 1 |
| Allen-Mersh, TG | 1 |
| Pettavel, J | 4 |
| Morgenthaler, F | 3 |
| Buroker, T | 1 |
| Samson, M | 1 |
| Correa, J | 1 |
| Fraile, R | 1 |
| Schabel, FM | 1 |
| Herbsman, H | 1 |
| Hassan, A | 1 |
| Gardner, B | 1 |
| Harshaw, D | 1 |
| Bohorquez, J | 1 |
| Alfonso, A | 1 |
| Newman, J | 1 |
| Lee, YT | 1 |
| Webber, BM | 1 |
| Soderberg, CH | 1 |
| Leone, LA | 1 |
| Rege, VB | 1 |
| Glicksman, AS | 1 |
| Ensminger, WD | 1 |
| Rosowsky, A | 1 |
| Raso, V | 1 |
| Levin, DC | 1 |
| Glode, M | 1 |
| Come, S | 1 |
| Steele, G | 1 |
| Frei, E | 1 |
| Hersh, EM | 1 |
| Hall, SW | 1 |
| Menachem, YB | 1 |
| Granmayeh, M | 1 |
| McBride, CM | 2 |
| Oberfield, RA | 3 |
| Helson, L | 1 |
| Helson, C | 1 |
| Peterson, RF | 1 |
| Das, SK | 1 |
| Ryan, R | 1 |
| Metman, EH | 1 |
| Oberfield, R | 1 |
| Glouse, M | 1 |
| Ishiwata, K | 1 |
| Takahashi, T | 1 |
| Iwata, R | 1 |
| Tomura, M | 1 |
| Tada, M | 1 |
| Itoh, J | 1 |
| Kameyama, M | 1 |
| Ido, T | 1 |
| Vogelzang, NJ | 1 |
| Vokes, EE | 1 |
| Charette, J | 1 |
| Whitman, G | 1 |
| Colleoni, M | 1 |
| Bajetta, E | 1 |
| de Braud, F | 1 |
| Zilembo, N | 1 |
| Nolè, F | 1 |
| Nelli, P | 1 |
| Hrushesky, WJ | 1 |
| von Roemeling, R | 1 |
| Lanning, RM | 1 |
| Rabatin, JT | 1 |
| Lorenz, M | 1 |
| Hottenrott, C | 1 |
| Inglis, R | 1 |
| Kirkowa-Reimann, M | 1 |
| Welch, DR | 1 |
| Aeed, PA | 1 |
| Estrada, J | 1 |
| Liebman, IM | 1 |
| Maguire, HC | 1 |
| Modest, EJ | 1 |
| Rochlin, DB | 1 |
| Smart, CR | 1 |
| Wolberg, WH | 1 |
| Burrows, JH | 1 |
| Talley, RW | 1 |
| Drake, EH | 1 |
| Tucker, WG | 1 |
| Brulé, G | 1 |
| Hane, S | 1 |
| Swinton, NW | 2 |
| Nahra, KS | 2 |
| Scherer, WP | 1 |
| Meyza, J | 1 |
| Johnson, FD | 1 |
| Jacobs, EM | 1 |
| Cady, B | 2 |
| Ratner, LH | 1 |
| Weiner, MJ | 1 |
| Cohen, SM | 1 |
| Greenspan, EM | 1 |
| Kaufman, S | 1 |
| Jones, PA | 1 |
| Taderera, JV | 1 |
| Hawtrey, AO | 1 |
| Baden, H | 1 |
| Sanderson, TA | 1 |
| Bloomenthal, ED | 1 |
| Spellberg, MA | 1 |
| Morgenthaler, FR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006[NCT00701168] | 0 participants | Expanded Access | No longer available | ||||
| A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691] | Phase 1 | 10 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for floxuridine and Neoplasm Metastasis
| Article | Year |
|---|---|
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
Rationale for adjuvant chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi | 1977 |
Nonsystemic treatment of metastatic tumors of the liver--a review.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1978 |
[Chemotherapy of cancer of the rectum and the colon].
Topics: Antimetabolites; Colonic Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; Injections, I | 1970 |
5-Fluorouracil in the treatment of gastrointestinal neoplasia.
Topics: Administration, Oral; Antineoplastic Agents; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; | 1973 |
24 trials available for floxuridine and Neoplasm Metastasis
| Article | Year |
|---|---|
UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2013 |
Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2010 |
Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Floxuridine; Fluorouraci | 2003 |
The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2003 |
[Immunotherapy of metastatic renal cell carcinoma: report of 28 cases].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2004 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothe | 2005 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineop | 2007 |
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged; Neo | 1995 |
Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Diarrhea | 1994 |
A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 1994 |
Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Female; Floxuridine; Humans; | 1993 |
Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Floxurid | 1993 |
Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedul | 1993 |
Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 1996 |
Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.
Topics: Adult; Female; Floxuridine; Fluorine Radioisotopes; Humans; Iodine Radioisotopes; Male; Middle Aged; | 1997 |
Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbop | 1997 |
Clinical trial of intrathecal administration of 5-fluoro-2'-deoxyuridine for treatment of meningeal dissemination of malignant tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Female; Floxuridine; Follow-Up Studies; Huma | 1999 |
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2001 |
Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil.
Topics: Adult; Aged; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Injection | 1976 |
Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carci | 1992 |
Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Circadian Rhythm; Female; Floxuridine; Humans; Infusion Pumps; K | 1990 |
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 1989 |
56 other studies available for floxuridine and Neoplasm Metastasis
| Article | Year |
|---|---|
Selective depletion of metastatic stem cells as therapy for human colorectal cancer.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Disease Models, Animal; Drug Therapy; Floxurid | 2018 |
First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases.
Topics: Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Hu | 2016 |
Bifunctional conjugates comprising β-cyclodextrin, polyethylenimine, and 5-fluoro-2'- deoxyuridine for drug delivery and gene transfer.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta-Cyclodextrins; Cell Cycle; Cell Line, Tumor; Cell Pr | 2010 |
Combination therapy by trastuzumab with 5'-deoxy-5-fluorouridine and cyclophosphamide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplas | 2009 |
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo | 1964 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
RESPONSE OF PRIMARY UNKNOWN CANCERS TO TREATMENT WITH 5-FLUOROURACIL (NSC-19893).
Topics: Adolescent; Biomedical Research; Child; Cyclophosphamide; Floxuridine; Fluorouracil; Geriatrics; Neo | 1964 |
HEPATIC ARTERY CATHETERIZATION FOR PROLONGED INFUSION CHEMOTHERAPY OF LIVER CANCER.
Topics: Anatomy; Angiography; Bile Duct Neoplasms; Biopsy; Catheterization; Equipment and Supplies; Floxurid | 1964 |
CANCER CHEMOTHERAPY OF THE GASTROINTESTINAL TRACT WITH REFERENCE TO INTRA-ARTERIAL INFUSION AND IRRADIATION.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cobalt Isotopes; Cyclophosphamide; | 1965 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials | 2004 |
Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs.
Topics: Amino Acids; Animals; Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Line; Cell Line, Tumor; Ce | 2005 |
Perfusion chemotherapy for colorectal liver metastases: a randomized study comparing FUDR against 5-FU/BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neoplasms; Floxuridine; Fluor | 1989 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2007 |
Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1983 |
Kinetics and metabolism of a new fluoropyrimidine, 5'-deoxy-5-fluorouridine, in humans.
Topics: Colonic Neoplasms; Drug Evaluation; Floxuridine; Humans; Isomerism; Kinetics; Neoplasm Metastasis; P | 1983 |
The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Floxuridine; Humans; Infusions, Intra- | 1981 |
[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors].
Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepa | 1983 |
Implanted pump concentrates chemotherapy for liver cancer.
Topics: Arteries; Floxuridine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Neoplasm Metastasis | 1981 |
Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Female; Floxuridine; Fluorouracil; Humans; | 1995 |
[Antitumor activity of various cytostatics in mice bearing murine advanced tumors].
Topics: Animals; Antineoplastic Agents; Cachexia; Cyclophosphamide; Drug Screening Assays, Antitumor; Floxur | 1993 |
[A case of breast cancer with multiple organ metastases in which single low dose administration of 5'-DFUR proved effective].
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; | 1993 |
Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; | 1998 |
Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Divisi | 2001 |
P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases.
Topics: Adult; Antimetabolites, Antineoplastic; Binding Sites; Codon; Colorectal Neoplasms; DNA Mutational A | 2001 |
[Hepatic metastases of cancers of the large intestine. Results of arterial chemotherapeutic treatment].
Topics: Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Intestinal Neoplasms; Intesti | 1976 |
Treatment of hepatic metastases with a combination of hepatic artery infusion chemotherapy and external radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Catheterization; Cobalt Radioisotopes; Colonic Neoplasms; Female | 1978 |
A combined treatment approach to management of hepatic metastasis.
Topics: Bone Marrow; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms | 1978 |
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.
Topics: Adult; Aged; Drug Evaluation; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, | 1978 |
Hepatic arterial infusion of Corynebacterium parvum and chemotherapy.
Topics: Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma; Catheterization; Female; Floxuridine; He | 1978 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
A rationale for the treatment of metastatic neuroblastoma.
Topics: Antineoplastic Agents; Bucladesine; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combina | 1976 |
[Fluorinated pyrimidines administered by percutaneous arterial perfusion in primary or secondary cancers of the liver].
Topics: Carcinoma, Hepatocellular; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neopl | 1977 |
Tumor diagnosis by PET: potential of seven tracers examined in five experimental tumors including an artificial metastasis model.
Topics: Animals; Carbon Radioisotopes; Deoxyglucose; Diagnosis, Differential; Disease Models, Animal; Floxur | 1992 |
Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance; | 1992 |
Development and characterization of a rat model for locally recurring mammary tumors: sensitivities to 5-fluoro-2'-deoxyuridine, adriamycin, and X-irradiation.
Topics: Animals; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Femal | 1988 |
The treatment of hepatic metastases by long-term chemotherapeutic infusions.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Evaluation Studies as Topic; Female; | 1970 |
Maintenance of delayed hypersensitivity reactions in patients receiving cancer chemotherapy.
Topics: Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Immunity; Ma | 1968 |
Formal discussion: future prospects in leukemia chemotherapy.
Topics: Animals; Dactinomycin; Floxuridine; Leukemia; Melphalan; Mercaptopurine; Methotrexate; Mitomycins; N | 1965 |
An evaluation of 51 patients with hepatic artery infusion.
Topics: Antineoplastic Agents; Catheterization; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Hepat | 1966 |
Determinants of human tumor sensitivity to fluorinated pyrimidine chemotherapy.
Topics: DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Ligases; Neoplasm Metastasis; | 1967 |
Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of liver.
Topics: Adenocarcinoma; Catheterization; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Hepatic Arte | 1967 |
[Our experience with 5-fluoro-2-desocyuridine].
Topics: Adult; Aged; Colonic Neoplasms; Female; Floxuridine; Gallbladder Neoplasms; Humans; Liver Neoplasms; | 1968 |
The evolution of colorectal cancer.
Topics: Colonic Neoplasms; Floxuridine; Humans; Infusions, Parenteral; Liver Neoplasms; Lymphatic Metastasis | 1968 |
[Chemotherapeutic treatment of liver metastases as a function of their spontaneous evolution].
Topics: Floxuridine; Humans; Liver Neoplasms; Methotrexate; Neoplasm Metastasis | 1969 |
Chemotherapy of metastatic malignant melanoma. Experience with 73 patients.
Topics: Adult; Aged; Antineoplastic Agents; Chlorambucil; Colchicine; Cyclophosphamide; Cytarabine; Eye Neop | 1971 |
Arterial infusion chemotherapy of liver metastases arising from rectal and colonic cancer.
Topics: Colonic Neoplasms; Floxuridine; Humans; Injections, Intra-Arterial; Liver Function Tests; Liver Neop | 1970 |
Practical aspects of investigation and treatment of colorectal cancer.
Topics: Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusions, Parenteral; Liver Function | 1972 |
Chemotherapy of colon and rectal cancer.
Topics: Administration, Oral; Antigens, Neoplasm; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasm | 1972 |
Transformation of hamster cells in vitro by 1- -D arabinofuranosylcytosine, 5-fluorodeoxyuridine and hydroxyurea.
Topics: Animals; Cell Transformation, Neoplastic; Cricetinae; Culture Techniques; Cytarabine; Cytosine Nucle | 1972 |
Regional infusion chemotherapy of hepatic metastases from carcinoma of the colon.
Topics: Age Factors; Aspartate Aminotransferases; Catheterization; Chemotherapy, Cancer, Regional Perfusion; | 1974 |
Infusion of liver tumours.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Floxurid | 1968 |
[Continuous intra-arterial infusion of 5-fluor-2-deoxyuridine in primary and metastatic liver cancer].
Topics: Adenoma, Bile Duct; Adult; Aged; Arteries; Carcinoma, Hepatocellular; Female; Floxuridine; Gastroint | 1968 |
Experience with hepatic arterial infusions.
Topics: Adult; Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorouracil; Gall | 1971 |
Therapy for carcinoma of the liver.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Angiography; Aspartate Aminotransferases; Carcino | 1971 |
[Combined drug-surgical treatment in primary and secondary liver tumors].
Topics: Carcinoma, Hepatocellular; Drug Therapy, Combination; Floxuridine; Humans; Injections, Intra-Arteria | 1974 |